Company profile
Focus on proprietary Chinese medicine, chemical medicine research and development, production and sales. As of the date of signing of the letter of intent, the company has 11 production lines, such as tablets, granules, capsules, soft capsules, powder, powder injection, lyophilized powder injection, API, traditional Chinese medicine extraction, small volume injection, etc., a total of 68 drug approval numbers have been obtained, of which 17 are selected in the National essential Drug Catalog and 48 in the National Medical Insurance Catalog. Over the years, the company has worked hard in the digestive system, mental nervous system, otorhinolaryngology and other key treatment areas, forming a complementary development trend of Chinese and Western medicine and a unique series of product layout.
The highlight of the company
(1) the company has a wide range of products, covering many potential areas such as digestive system, mental nervous system, otorhinolaryngology, cardio-cerebrovascular system, immune system and so on. As of the date of signing of this letter of intent, the company has obtained 68 drug registration documents. The company has Weidimei (magnesium aluminum carbonate tablets), tangerine ice plum tablets, Duliang soft capsules, Changsong (polyethylene glycol 4000 powder), Tongxiening granules and other products with competitive advantages in market segments, the company's products treat common diseases and frequently-occurring diseases, the product life cycle is long, safe and effective, cost-effective. In addition to the above main products, the company also has exclusive patented products Liuwei Anshen capsule, Bawei Qilong granule, the country's first imitation product Oudman (terazosin hydrochloride capsule), Gabexate for injection, pefloxacin mesylate for injection, and omeprazole sodium for injection, citicoline sodium for injection, Shangqing tablets and other products with strong market potential. In order to further enrich the product line and tap new revenue growth points, the company obtains more drug registration documents, machine production and listing through self-research and development, cooperative research and development, technology transfer and other ways. As of the date of signing this letter of intent, the company has a total of nearly 20 products under research.
(2) the company's sales network has covered 31 provinces, municipalities and autonomous regions. The company has strong control over sales channels, and its products have a high share in hospitals, chain drugstores and other major sales channels, and now it has covered more than 3100 hospitals across the country. The professional marketing team is conducive to the control of the company's sales channels and end customers, is conducive to the overall promotion and dissemination of the company's brand, and lays a solid foundation for the company to further develop the market. The company's main products Weidimei (magnesium aluminum carbonate tablets), Ganju Bingmei tablets, Duliang soft capsules, Changsong (polyethylene glycol 4000 powder) and Tongxiening granules have established extensive popularity and good reputation in the market, and the market share of hospitals in the subdivision industry ranks in the forefront.
